Document is current
Any future updates will be listed below
-
Authors
Lee, Tae Hoon https://orcid.org/0000-0002-4723-3931
Chang, Ji Hyun https://orcid.org/0000-0001-5921-5522
Jang, Bum-Sup https://orcid.org/0000-0002-7064-9855
Kim, Jae Sik https://orcid.org/0000-0002-0039-8667
Kim, Tae Hyun https://orcid.org/0000-0001-8413-3385
Park, Won https://orcid.org/0000-0003-4686-2071
Kim, Yong Bae https://orcid.org/0000-0003-4884-2330
Kim, Su Ssan https://orcid.org/0000-0002-8473-302X
Han, Wonshik https://orcid.org/0000-0001-7310-0764
Lee, Han-Byoel https://orcid.org/0000-0003-0152-575X
Shin, Kyung Hwan https://orcid.org/0000-0002-5852-7644
- License Information
-
More Information
Article History
Received: 22 September 2022
Accepted: 3 November 2022
First Online: 16 November 2022
Declarations
:
: Protocol of the PORT-N1 trial was approved by Institutional Review Board of Seoul National University Hospital (number H-2205-167-1328). Protocol version 1.0 was approved on June 27, 2022. All clinical treatments are conducted in accordance to International Good Clinical Practice Guidelines and the Declaration of Helsinki. Written consent is obtained from each participant before enrollment. Participants are aware of the purpose, potential advantages, and risks of the trial.
: Not applicable.
: The authors declare that they have no competing interests.
